Clinical Trials

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04172532 2026-04-13

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Phase 1/2 Recruiting

92 enrolled

Pancreatic Neoplasms

NCT04310020 2026-04-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

47 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

486 enrolled

Phase NA Not yet recruiting

Urinary Bladder Neoplasms

NCT07507058 2026-04-02

Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma

60 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07276360 2026-03-27

HypoRTCx-UG

Phase NA Active not recruiting

278 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05318274 2026-03-23

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

72 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Phase NA Active not recruiting

Prostate Adenocarcinoma

NCT04624256 2026-03-13

GARUDA

208 enrolled

Prostatic Neoplasms

NCT01266642 2026-03-11

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

301 enrolled 9 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02701153 2026-03-10

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

51 enrolled

Phase 1/2 Active not recruiting

NCT04454528 2026-03-10

BreastVAX

27 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT04708067 2026-03-05

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

2 enrolled

Cholangiocarcinoma

NCT07447570 2026-03-03

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00809991 2026-02-18

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

91 enrolled 12 charts

Prostatic Neoplasms

NCT04278118 2026-02-17

HiPPI

70 enrolled

CNSEndocrine

Brain Neoplasms, Meningioma, Neurilemmoma, Pituitary Neoplasms, Nerve Sheath Neoplasms

NCT03796767 2026-01-28

SOAR

20 enrolled 26 charts

Lymphatic Metastasis, Prostatic Neoplasms

NCT05109494 2026-01-28

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

30 enrolled

NCT04862455 2026-01-23

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Terminated

14 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07188532 2026-01-23

BEAR

141 enrolled

Phase 2 Not yet recruiting

Sarcoma, Ewing

NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

25 enrolled

Small Cell Lung Carcinoma

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Phase 3 Recruiting

118 enrolled

Prostatic Neoplasms

NCT06559540 2026-01-09

SWIFT RT

220 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

40 enrolled

Other solid neoplasm

Advanced Refractory Solid Tumors

NCT02912312 2026-01-07

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

805 enrolled

Breast Neoplasms

NCT03345420 2025-12-30

NOVEMBER

102 enrolled 12 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04683653 2025-12-29

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Phase 1/2 Recruiting

100 enrolled

Gynecologic

Endometrial Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

120 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT02783690 2025-12-04

A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation

88 enrolled 17 charts

Breast Neoplasms

NCT03624478 2025-11-26

Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery

25 enrolled 11 charts

Phase 3 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

186 enrolled

Prostatic Neoplasms

NCT03570827 2025-09-03

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

52 enrolled

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT07084519 2025-07-24

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

190 enrolled

Breast Neoplasms

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06435260 2025-06-26

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

30 enrolled

Phase NA Active not recruiting

Pancreatic Neoplasms

NCT06443359 2025-06-11

Hypofractionated Regional Nodal Irradiation in Breast Cancer

56 enrolled

Breast Neoplasms, Lymphedema

NCT05136846 2025-06-04

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Phase 1 Recruiting

28 enrolled

Lung Neoplasms

NCT05439278 2025-05-21

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

Phase 3 Recruiting

178 enrolled

CNS

Glioblastoma

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

17 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT04398095 2025-04-30

HOT

Phase NA Completed

20 enrolled

Neoplasms, Radiation-Induced, Sarcoma

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Phase 1 Active not recruiting

Locally Recurrent Rectal Cancer

NCT04106856 2025-04-06

SHAPER

22 enrolled

Pancreatic Neoplasms

NCT03035890 2025-04-01

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

Phase NA Completed

35 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02819843 2025-01-29

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

19 enrolled 7 charts

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT06796270 2025-01-28

Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma

24 enrolled

Nasopharyngeal Carcinoma

NCT03972930 2025-01-17

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

48 enrolled

Phase 3 Active not recruiting

NCT01444820 2024-12-04

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

329 enrolled

Prostatic Neoplasms

NCT06160206 2024-11-19

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma